Q1 EPS of $1.03 topped estimates, as noninterest income rose 5% and loan balances increased 2.1% year over year. Operating leverage improved by 270 bps with expenses well-managed and credit loss provisions down 2.9% amid better credit quality. Feel unsure about the market's next move?

Melinda French Gates, co-founder of the Gates Foundation and founder of Pivotal Ventures, recently opened up about navigating life's major shifts, while emphasizing the importance of not rushing through significant transitions, referring to the period between changes as a valuable "clearing" - a ...

Tesla halts plans to ship Cybercab and Semi electric truck parts from China as the U.S.-China trade war intensifies. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.

Bill Ackman's Pershing Square Capital Management purchases 12.71 million shares of Hertz. Pershing Square's stake was valued at approximately $46.5 million at the time of the filing. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt ...

Expansion to 50 EH/s on track for H1 2025 Expansion to 50 EH/s on track for ...

UAB "Atsinaujinančios energetikos investicijos" ( the Company ) publishes its audited annual consolidated and separate financial statements for 2024 together with Company's and Group's annual report for ...

Industry Veteran Joins Draganfly to Drive Innovation at the Intersection of Public Safety and Technology ...

The ostensible reason why the market rallied on Monday was the news from Friday night that the Trump administration was exempting items such as laptops and smart phones from its latest round of "reciprocal" tariffs on China. We decided to fade that rally for a few tariff-related reasons:

PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new ...

TORONTO, April 16, 2025 ( GLOBE NEWSWIRE ) -- Avicanna Inc. ( "Avicanna" or "Company" ) ( TSX: AVCN ) ( OTCQX: AVCNF ) ( FSE: 0NN ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce ...